Emerging Markets Earnings Roundup: Eli Lilly (Part 6)
This article was originally published in PharmAsia News
Executive Summary
China and emerging markets are expected to come to the fore for Eli Lilly as it works through patent expirations in the United States, while Japan helped despite a weaker yen.
You may also be interested in...
Lilly Not Ducking M&A, But Will Play To Strengths In Cancer And Diabetes
The Indiana-based big pharma will focus on product-level acquisitions in its core areas of strengths now that it has rounded out its animal health business with its $5.4 billion acquisition of Novartis Animal Health.
Lilly Feeds The Beast, But Is Novartis Animal Health Unit Worth The Price?
$5.4 billion deal boosts Lilly’s Elanco animal health business that adds both geographic scope and better product mix, but some investors snort at the high multiple.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.